Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDP870 studies

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Preliminary data from a Phase III trial examining the pegylated TNF inhibitor in combination with methotrexate in patients with moderate to severe rheumatoid arthritis is positive, Celltech reports. A significant response in the primary endpoint, ACR20, was seen at week one and maintained for the study's six-month duration. A Phase III monotherapy trial is slated to conclude in the third quarter. Celltech plans to commence the remainder of the Phase III program in the second half of 2004. Pfizer had decided to delay initiation of further Phase III studies until results from the RA studies were seen. Phase III trials in Crohn's disease are ongoing, with submission planned for 2005...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel